## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

				of:

Angel CEBOLLA RAMIREZ et al Atty. Docket No. 027318-00021

Serial No.: New Application

Examiner:

Filed: May 30, 2006

Art Unit:

METHOD OF REGULATING HETEROLOGOUS PROTEIN EXPRESSION CONTROLLED BY SALICYLIC DERIVATIVES IN MICRO-ORGANISMS

ASSOCIATED WITH HIGHER ORGANISMS

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: May 30, 2006

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

• •		Ū		• •		
	merits	U.S. filing in the p	formation Disclosure St g date, OR (b) before t resent application, OR No certification or fee is	he mailing date of (c) accompanies a	f a first Office Action of	n the
		he U.S. 1	formation Disclosure St iling date AND after the ore the mailing date of	e mailing date of the	he first Office Action o	n the
		foreign	I hereby certify that eaction Disclosure Statem patent office in a count prior to the filing of this e)(1).	ent was first cited erpart foreign app	in a communication for the communication for	n three
		Disclos office in reason	I hereby certify that no ure Statement was cite a counterpart foreign able inquiry, was known more than three mon	d in a communica application or, to in to any individual	ition from a foreign pa my knowledge after m designated in 37 CFF	aking

## Disclosure Statement. 37 CFR §1.9 (1972) RGC (1974) 30 MAY 2006 C. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information. 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the

a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300

as needed to ensure consideration of the disclosed information.

- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- 4. The reference(s) was/were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully submitted,

Richard JV Berman Registration No. 39,107

Customer No. 004372 ARENT FOX PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RJB/ars

Enclosures: International Search Report; Form PTO-SB08a; References (6)

AP20 ROS OFFICE 3 O MAY 2005

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Collection of information unless it contains a valid OMB control number.

	Under the Paperwork	k Reduction	оп Ас	t of 1995, no persons	are required to respond to a collection	on of information unless it contains a valid OMB control number.		
	Substitute for form 1449A/I	PTO			Complete if Known			
	INFORMATION	DICC	<b>&gt;1</b>	CUDE	Application Number	New Application 20102		
	INFORMATION				Filing Date	May 30, 2006		
	STATEMENT B			ICANT	First Named Inventor	Angel CEBOLLA RAMIREZ et al		
Form PTO/SB/08a					Art Unit			
					Examiner Name			
Sheet	1	C	of	1	Attorney Docket Number	027318-00021		

			U.S. P.	ATENT DOC	JMENTS	
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code <sup>2</sup> (if known)	Publication Date Name of Patentee or MM-DD-YYYY Applicant of Cited Documer		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2003/0113293	A1	06-19-2003	David G. BERMUDES et al	
		US-2001/0016354	A1	08-23-2001	Angel CEBOLLA RAMIREZ et al	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
- "	<u> </u>	US-				
-		U\$-				
		US-				
		US-				
		US-				
		US-				
		US-				
	<u> </u>	US-				

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code <sup>3</sup>	Alumbari	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
->-		03063593	wo	Α	08-07-2003	Vion Pharmaceuticals, Inc.			
	ļ								
	<u> </u>								
	ļ								
	ļ								
	ļ								
	<u> </u>								
	<del> </del>		_						
	-				•				
	<del>                                     </del>	<del></del>							

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code. \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known. New Application 20 4 4 5 **Application Number** INFORMATION DISCLOSURE May 30, 2006 Fiting Date STATEMENT BY APPLICANT Angel CEBOLLA RAMIREZ et al First Named Inventor Form PTO/SB/08b Art Unit **Examiner Name** 027318-00021 **Attorney Docket Number** 1 Sheet

<del>-</del>		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		M.C. SULAVIK et al; The Salmonella Typhimurium Mar Locus; Molecular and Genetic Analyses and Assessment of its Role in Virulence; J. Bactoriol., 1997; Vol. 179; No. 6; pages 1857-1866.	
		J.M. PAWELEK et al; Bacteria as Tumour-Targeting Vectors; Lancet Oncol; 2003; Vol. 4; No. 9; pages 548-556.	_
		A. CEBOLLA et al; Rational Design of a Bacterial Transcriptional Cascade for Amplifying Gene Expression Capacity; Nucleic Acids Res; 2001; Vol. 29; No. 3; pages 759-766	
		A. CEBOLLA et al; Improvement of Recombinant Protein Yield by a Combination of Transcriptional Amplification and Stabilization of Gene Expression; <i>Appl. Environ. Microbiol</i> ; 2002; Vol. 68; No. 10; pages 5034-5041.	
		S. P. COHEN et al; Salicylate Induction of Antibiotic Resistance in Escherichia Coli; Activation of the Mar Operon and A Mar-Independent Pathway; <i>J. Bacteriol</i> ; 1993; Vol. 175; No. 24; pages 7856-7862	
-			
	1		
	+		
	1		
	<del> </del>		
	<del> </del>		
		<u></u>	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.